Introduction
The human INK4A/ARF locus located on chromosome 9p21 attracts the attention of many oncologists, because it encodes two different candidate tumor suppressors, p16 INK4A and p14 ARF , which affect Rb and p53 pathways, respectively.
1,2 p16
INK4A is a cyclin-dependent kinase inhibitor (CKI) specific to CDK4 and CDK6 and can directly block cyclin Ddependent kinase activity. 3 The cyclin D/CDK4 (or 6) complex facilitates G1-phase progression toward the S phase by phosphorylating and thus inactivating the Rb protein (pRb). 4 Therefore, the upregulated expression of p16
INK4A causes G1-phase arrest and function is dependent on normal Rb. 5, 6 In contrast, transcription of p16 INK4A is repressed by Rb function. 7 Once cells lack Rb, the levels of p16
INK4A mRNA and protein were elevated without growth arrest. 8, 9 The aberrantly high expression of p16 INK4A was evident in tumors without functional Rb. 3,7 p16 INK4A is a member of the INK4 family that has three other structurally related members, p15 INK4B , p18 tumor suppressor genes. 10, 11 In human hematological malignancies, their inactivation occurs mainly by means of homozygous deletion or promoter region hypermethylation (reviewed in Ref. 12) . In tumors such as pancreatic adenocarcinomas, esophageal squamous cell carcinomas and familial melanomas, p16
INK4A is often inactivated by point mutation, which is not the case in hematological malignancies. 12 On the other hand, genetic aberrations of p18 INK4C or p19 INK4D are rare in human tumors. 12 The INK4A/ARF locus yields two transcripts derived from alternative first exons, exon 1␣ and exon 1␤, each of which is joined to sequences in exon 2.
13,14 p16 INK4A is translated from the ␣ form transcript derived from exon 1␣. The ␤ form transcript that has an initiation codon in exon 1␤ encodes an unrelated protein, the reading frame of which differs from that of p16 INK4A ; it is designated ARF, derived from an alternative reading frame protein.
14 Ectopic expression of mouse p19 ARF in the nucleus of rodent fibroblasts induces G1 and G2 phase arrest. 14 Transfection of human ARF cDNA induces marked growth inhibition in head and neck squamous cell carcinoma cell lines and HeLa cells with nonfunctional Rb, 15 while growth suppression by p16
INK4A requires functional Rb. 5, 6 Thus, ARF is thought to function negatively on cell-cycle progression, in a manner different from p16
INK4A
. Human ARF protein, predicted to be 13 902 Da, is referred to as p14 ARF . 16 ARF is also a candidate tumor suppressor, because mice lacking p19
ARF develop tumors and mouse embryo fibroblasts lacking p19 ARF are transformed by oncogenic Ha-ras alone. 17 Furthermore, in patients with T cell acute lymphoblastic leukemia (T-ALL) and rearranged alleles of this region, p14 ARF encoding exons are always disrupted or deleted, whereas p16 INK4A and p15 INK4B encoding exons are spared in some patients. 18 The human p14 ARF binds directly to MDM2, resulting in stabilization of both p53 and MDM2, which induces p21
Cip1 expression and cell-cycle arrest in both G1 and G2/M. 16 In contrast, p14 ARF is negatively regulated by wild-type p53 expression, resulting in a negative feedback loop. 16, 19 p14 ARF can be inactivated by homozygous deletion, 18 and promoter region hypermethylation, 19 while mutations in exon 1␤ are not found in tumor-derived lung, bladder, glioma or melanoma cell lines or in primary T-ALL cells. 18 DNA alterations and methylation status of the p16 INK4A gene in hematological malignancies have been frequently examined. 12 However, expression of p16 INK4A and especially p14 ARF in primary hematological malignancies has not been described in detail. We investigated the expression of p16 INK4A and p14 ARF in primary hematological malignancies and hematopoietic cell lines using a quantitative reverse transcriptionpolymerase chain reaction (RT-PCR) assay. We found that INK4A/ARF expression was often altered and differs among hematological malignancies. Patients with follicular lymphoma (FL) and increased p14 ARF expression are likely to have a poor prognosis. 
Data from other studies (see Results and Discussion for references). b HS-sultan is a derivative of Jijoye, which has mutated p53. 
Clinical specimens of hematological malignancies
We examined a total of 137 tissue specimens from 137 patients in Japan with hematological malignancies. The specimens had been frozen with dimethyl sulfoxide in liquid nitrogen or in deep freezers at −80°C, until RNA preparation but some were freshly prepared. These patients were selected from the files of the Fourth Department of Internal Medicine, School of Medicine, University of Tokyo (Tokyo) between December 1985 and October 1998, Department of Hematology, Showa General Hospital (Tokyo) between March 1992 and February 1996, and Cancer Institute Hospital (Tokyo) between November 1993 and February 1996, on the basis of availability of frozen or fresh samples for molecular studies.
The proportion of malignant cells in each sample was greater than 70%, judged with cytosmears. Eight patients had been referred from Nagano Red Cross Hospital (Nagano), Kurobe City Hospital (Toyama) and Teikyo University Ichihara Hospital (Chiba). Some of the specimens were obtained with written informed consent and others were archive specimens obtained at diagnostic procedures. The patients (87 men and 50 women) ranged in age from 14 to 89 years (median age: 59 years). Tissues examined included 69 lymph nodes, 34 bone marrow (BM) aspirates, 24 peripheral blood (PB) samples, seven pleural effusions, one peritoneal effusion and two extranodal tumors. The hematological malignancies in these patients are listed in Table 2 . Among them, 93 patients (66 non-Hodgkin's lymphomas (NHLs), 10 acute lymphoblastic leukemias (ALLs), four multiple myelomas (MMs), three chronic lymphocytic leukemias (CLLs), and two prolymphocytic leukemias (PLLs), two Waldenströ m's macroglobulinemias (WMs), six adult T cell leukemia/lymphomas (ATLs)) were included in our previous studies on cyclin D1 overexpression. 20, 21 Survival time was measured from the time of pathologic diagnosis of the disease and from the time of sampling for molecular analysis. (9) 19 (3) 18 (3) 42 (6) 1 (0) a One patient with T-CLL is included and expressed both genes. b Four patients with T-ALL are included and expressed both genes. PCL, plasma cell leukemia; WM, Waldenströ m's macroglobulinemia; CLL, chronic lymphocytic leukemia; PLL, prolymphocytic leukemia; CML-BC, blast crisis of chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia; LBL, lymphoblastic lymphoma. Numbers of cyclin D1-overexpressing patients are given in parentheses.
Normal PB samples (n = 4) were obtained from healthy adult volunteers with informed consent. Normal BM aspirates (n = 3) from patients with NHL, without BM involvement, were obtained following acquisition of informed consent.
RNA preparation
RNAs of cell lines were extracted from exponentially growing cells by the acid guanidinium thiocyanate-phenol-chloroform (AGPC) method, 22 boiled for 1 min, measured by optic density, and stored at −80°C. Frozen cells were thawed rapidly in a bath prewarmed at 37°C, and subsequently, RNAs of these cells were extracted by the AGPC method. From freshly prepared PB or BM, mononuclear cells (MNCs) were separated by standard Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) density-gradient centrifugation, as outlined by the manufacturer. Fresh lymph node cells were prepared by sieving minced lymph nodes. RNAs of these cells were also extracted by the AGPC method.
cDNAs and Northern blot analysis
The cDNA plasmids used in this study were as follows: a p16 INK4A (␣ form) cDNA plasmid was kindly provided by Dr David Beach, Howard Hughes Medical Institute; a plasmid containing the insert of the ␤ form transcript (clone 13) was kindly provided by Dr Christian-Jacques Larsen, INSERM. 13 Probes used for Northern blot analysis are as follows: a probe specific to exon 1␣ of p16
INK4A was a 150 bp PCR product obtained by PCR using primers (P16AS206, P16S57; see Table  3 ) from the p16 INK4A cDNA plasmid. A probe specific to exon 1␤ of p14 ARF was a 197 bp PCR product obtained by PCR using primers (P16AS206, P16BS40; see Table 3 ) from clone 13. These two probes were 32 P-radiolabeled with each anti- Table 3 Primers used for PCR amplification Name Sequence Primer length (bp)   P16AS206  5Ј-TGCCCATCATCATGACCTGG-3Ј  20  P16S57  5Ј-GGAGCAGCATGGAGCCTT-3Ј  18  P16BS40  5Ј-TTCTTGGTGACCCTCCGGATT-3Ј  21  BA299S  5Ј-GCACCACACCTTCTACAATG-3Ј  20  BA538ASP16AS  5Ј-TGCCCATCATCATGACCTGGTAGATGGGCACAGTGTGGGT-3Ј  40 sense PCR primer and Klenow fragment (Takara, Kyoto, Japan). A ␤-actin probe was a human ␤-actin 0.63-kb cDNA fragment, which was 32 P-radiolabeled using a random primer labeling kit (Takara). An aliquot (10 g/lane) of each total RNA was separated on a formaldehyde-agarose gel and blotted on to nitrocellulose membrane. The membrane was hybridized with each 32 P-labeled probe as described, 20 washed in high stringency of 0.1-0.2 × SSC and 0.1% sodium dodecyl sulfate (SDS) at 65°C and autoradiographed at −80°C with an intensifying screen.
RT-PCR
cDNA was synthesized with oligo(dT) 15 from total RNA, as described. 20 An aliquot (1 l) of cDNA (20 ng RNA equivalent) was placed in 20 l of 1 × PCR buffer (10 mm TrisHCl, 50 mm KCl, 1.5 mm MgCl 2 , pH 8.3) with 200 m each deoxyribonucleoside triphosphate (dNTP), 0.2 m each primer (P16AS206, P16S57, P16BS40, BA299S) except for BA538ASP16AS which were added at 0.5 nm, 2 Ci of ␣-32 P dCTP, 0.5 U recombinant Taq DNA polymerase (Takara), and 1 l dimethyl sulfoxide (Wako Pure Chemical Industries, Osaka, Japan). Reaction mixtures were overlaid with mineral oil (Sigma, St Louis, MO, USA) and PCR amplification was started by placing the capped tubes on the block in the DNA thermal cycler (Perkin Elmer, Norwalk, CT, USA) which had already been heated to over 90°C. Each cycle constituted denaturation (1 min at 94°C, first cycle 5 min), annealing (2 min at 64°C), and extension (3 min at 72°C, last cycle 10 min). PCR was run for 21 cycles unless otherwise stated. Five microliters of each PCR reaction were separated on a 4.5% polyacrylamide gel followed by autoradiography. An optical scanner was used and densitometrical analysis was made using NIH image 1.59 software (NIH, Bethesda, MD, USA). As negative controls, distilled water instead of cDNA or RT reactions without reverse transcriptase was subjected to PCR and we confirmed no false positive reaction.
PCR primers were synthesized by Greiner Japan (Tokyo, Japan) or GIBCO BRL (Tokyo, Japan) and are listed in Table  3 . Schematic presentation of design of the PCR primers is depicted in Figure 1a . Expected sizes of the PCR products are as follows: p16 INK4A , 150 bp; p14 ARF , 197 bp; ␤-actin, 260 bp. Three specific upstream primers, a shared downstream primer, and a composite downstream primer were used. The shared downstream primer, P16AS206, corresponded to 187-206 nucleotide (nt) in the sequence of p16 INK4A (␣ form) 3 and 217-236 nt in the sequence of p14 ARF (␤ form). 13 The upstream primer specific to p16 INK4A , P16S57, corresponded to 57-74 nt in the sequence. 3 The upstream primer specific to p14 ARF , P16BS40, corresponded to 40-60 nt in the sequence and was the same as P1 primer described by Duro et al. 13 The upstream primer specific to ␤-actin, BA299S, corresponded to 299-318 nt in the sequence of ␤-actin cDNA. 23 The 3Ј portion ARF and ␤-actin cDNA templates. The indicated template, ␤-actin, p14 ARF or p16 INK4A cDNA plasmid, was added at the indicated concentration while the other two were kept at 2 × 10 4 molecules/l for p14 ARF and p16 INK4A , and at 2 × 10 5 molecules/l for ␤-actin and PCR was done, as described in 'Materials and methods'. After electrophoresis, the gels were dried and exposed to X-ray films at −80°C with intensifying screens. Arrows indicate PCR products corresponding to p16 INK4A , p14 ARF and ␤-actin.
of the composite downstream primer, BA538ASP16AS, corresponded to 519-538 nt in the ␤-actin sequence 23 and the 5Ј portion was the same as P16AS206.
The level of p16 INK4A or p14 ARF expression was determined as the ratio of the signal of the p16 INK4A or p14 ARF PCR product to those of the internal control (␤-actin). RT-PCR for cyclin D1 overexpression was done, as described. 21 
Western blot analysis for pRb
Cells were lyzed with 1 × sample buffer (Tris-HCl 60 mm, SDS 2%, dithiothreitol 0.1 m, pH 6.8) and boiled for 5 min. Protein concentration was determined by spectrophotometry using BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). 24 A total of 30 g protein per lane was loaded on an 8% SDSpolyacrylamide gel and subjected to Western blot analysis, as described. 25 Anti-pRb monoclonal antibody (MAb1; TRITON Diagnostics, Alameda, CA, USA), at 0.4 g/ml, was used.
Statistical analyses
Univariate (Kaplan-Meier) analysis was used to assess survival differences. Survivals between different subgroups were compared using the Wilcoxon test. ) and control (␤-actin) in a tube was designed to circumvent difficulties in conventional competitive RT-PCR assays (Figure 1a) . Simple co-amplification of control and targets reveals the ratio of target to control templates by comparing target and control products generated during the exponential phase of the PCR reaction. 26 Since ␤-actin is expressed at a level much higher than those of the targets, comparable co-amplification can be difficult. Therefore, we used a composite primer at a low concentration to reduce ␤-actin signals at a constant ratio to the level comparable to the target signals.
Results

Quantitative RT-PCR
As shown in Figure 1a , we designed a common primer, P16AS206, derived from 16 bases in 5Ј end of exon 2 and four identical bases in 3Ј ends of exons 1␣ and 1␤, and a composite primer, BA538ASP16AS, the 3Ј part of which is derived from the sequence of ␤-actin and the 5Ј part of which is the same as the common primer, P16AS206. The three specific primers for p16 INK4A , p14
ARF and ␤-actin are P16S57, P16BS40 and BA299S, respectively. Amplification of ␤-actin cDNA must be initiated with BA299S and BA538ASP16AS, then, P16AS206 takes the place of BA538ASP16AS because we use BA538ASP16AS at a lower concentration. Final products for ␤-actin were made by virtue of P16AS206 and BA299S. We confirmed identity of the PCR products by direct sequencing (data not shown). We found exponential amplification phases of three genes overlapped up to 21 cycles with a cDNA from MEG-01s cell line used as a template (data not shown). Therefore, PCR was next run for 21 cycles. In addition, using cDNA plasmids for the genes as templates, we confirmed the ratio of PCR products reflecting that of added templates (Figure 1b) .
p16
INK4A and p14 ARF expression in hematopoietic cell lines
We studied p16 INK4A and p14 ARF mRNA expression in hematopoietic cell lines, by RT-PCR described above and Northern blot analysis. As shown in Figures 2a and b , the RT-PCR and Northern blot analysis gave similar results and thus, the quantitative nature of the PCR was re-confirmed. The RT-PCR had a more sensitive detectability.
In 22 (54%) of 41 cell lines, neither p16 INK4A nor p14 ARF mRNA was detected by the RT-PCR, which is consistent with frequent deletions of the INK4A/ARF locus in cell lines reported previously. 12, 27 In seven (17%) of 41 cell lines, only p14 ARF was detected, which might be related to p16 INK4A promoter hypermethylation (Table 1) . p14 ARF expression without p16
INK4A expression was frequently (4/11) observed in B cell lines, while it was infrequent (1/12) in non-HTLV-1-infected T cell lines (Figure 2c ). In contrast, p16
INK4A expression without p14 ARF expression was observed only in two non-HTLV-1-infected T cell lines, KOPT-K1 and PEER (Figure 2b ).
Li et al 7 reported that p16 INK4A mRNA accumulates to a high level in cells lacking Rb function and that transcription of p16
INK4A is repressed by Rb. Therefore, we studied pRb expression in these cell lines by Western blot analysis (Table  1) . However, reciprocal expression of p16 INK4A and pRb is not necessarily expected. ARF is reported to be expressed highly in cell lines lacking p53.
16 p53 mutation, deletion or rearrangement was noted in at least 18 of the cell lines listed in Table 1. 28-37 However, mutation of p53 and lack of p14 ARF expression were not mutually exclusive. Seven cell lines showed smears in Northern blot analysis of p14 ARF mRNA and JK-1 showed a smear of p16 INK4A mRNAs, although the RT-PCR revealed no corresponding signals (Table  1 and Figure 2b ). Among them, two cell lines (KOPT-K1 and SKW-3) also showed p14 ARF bands of aberrant sizes.
p16
INK4A and p14 ARF expression in patients with hematological malignancies
As shown in Figure 3a , in normal PB and BM MNCs and lymph nodes of reactive lymphadenitis, p14 ARF mRNAs were at low levels and p16 INK4A mRNAs were barely detectable. In clinical specimens of hematological malignancies, abnormally high expression levels of p16 INK4A and/or p14 ARF compared to normal tissues were frequently observed (Figure 3 ARF expression, thus corresponding to the relatively high incidence of p16 INK4A deletion in diffuse lymphoma (13%). 12 On the other hand, p16 INK4A expression was frequently undetectable in both DLBCL (15/23, 65%) and FL (13/30, 43%) . MM was similar in expression to FL. These findings are consistent with the previous reports that homozygous deletion of the INK4A/ARF locus in FL and MM is rare and that p16
INK4A is hypermethylated in 40% of FL and in 75% of MM. 12, 38, 39 In a study of p16 INK4A protein expression in NHLs by Western blot analysis, loss of expression was rare (6%) in typical FL but frequent (28%) in large cell lymphoma. 40 Two other immunohistochemical studies revealed that the incidence of p16
INK4A protein loss in FL is zero whereas in diffuse large lymphoma it is as high as 44-65%. 41, 42 Taken together, in a portion of FL, p16
INK4A may be hypermethylated and its mRNA levels may be low, but not low enough to silence protein expression. In almost all patients with acute myeloid leukemia (AML), both expressions were detectable, such being consistent with the rarity of homozygous deletion of INK4A/ARF locus in this disease. 12 High levels of p16 INK4A expression (defined as INK4A/␤-actin Ͼ0.2 arbitrarily) were significantly more frequent in those with acute leukemia, including ALL, AML and blast crisis of chronic myelogenous leukemia (CML-BC) than in other hematological malignancies (12/33 vs 6/104, P Ͻ 0.01, chi square test). We also examined cyclin D1 mRNA expression in these patients using the RT-PCR assay that we had devised; 20, 21 we identified 15 patients (six NHLs, one WM, five MMs, one CLL and two PLLs) with cyclin D1 overexpression. There was no apparent relationship between p16 INK4A and p14 ARF expression and cyclin D1 overexpression (Table 2) .
Clinical correlation
We then asked whether p16 INK4A or p14 ARF expression status affected overall survival time (OS) for patients with DLBCL or FL. We found no significant difference in OS between the presence and absence of p16
INK4A expression for patients with DLBCL or FL. Regarding p14 ARF expression, when survival time for patients with DLBCL was measured from the time of sampling for molecular analysis, patients with increased p14 ARF expression (p14 ARF /␤-actin Ͼ0.19) compared to normal controls tended to have a longer OS than did other patients (P = 0.096, Figure 4b ). Since all patients with FL expressed p14 ARF , we determined if the high levels of p14 ARF expression affected survival time. When high levels of p14 ARF expression were defined arbitrarily as p14 ARF /␤-actin Ͼ0.6, patients with high p14 ARF expression had a significantly shorter OS from the time of diagnosis than did other patients (P = 0.030, Figure 5a ). OS measured from the time of molecular analysis showed no significant difference (P = 0.21) ( Figure  5b ). We found no significant correlations of p14 ARF overexpression and other clinical parameters including age, LDH levels and clinical stage in FL.
Discussion
We used a quantitative RT-PCR assay to examine relative expression levels of p16 INK4A and p14 ARF in primary tumors of various hematological malignancies and hematopoietic cell lines. Major mechanisms of gene inactivation of this locus are homozygous deletion and hypermethylation, both leading to lack of expression. This assay cannot detect some modes of gene inactivation such as point mutation. However, p16
INK4A
inactivation by point mutation is rare in hematological malignancies 12 and mutations in p14 ARF exon 1␤ are not found in tumor-derived lung, bladder, glioma or melanoma cell lines or in primary T-ALL cells. 18 To maintain the quantitative nature of our RT-PCR assay, we limited the PCR cycles to 21 and the sensitivity of PCR is somewhat compromised. In reactive lymphoid tissues used as controls, p16
INK4A mRNAs were barely detectable with this assay, although p16
INK4A nuclear immunoreactivity has been reported. 41 p16 INK4A protein production from levels of p16 INK4A mRNA undetectable in our RT-PCR assay is possible and it should be noted that the 'lack of p16 INK4A expression' does not necessarily lead to complete silencing of the p16 INK4A gene. Therefore, our assay may overestimate the inactivation of p16
. However, it has as good a quantitative nature as Northern blot analysis and is useful when comparing the expression levels of p16 INK4A and p14 ARF mRNAs among a number of samples. To the best of our knowledge, this is the first report that characterizes simultaneously mRNA expression levels in various hematological malignancies.
Our results were fairly consistent with the genomic status of the p16
INK4A gene reported in hematopoietic cell lines (Table  1) . 12, 27, 37, 43, 44 In the cell lines in which p16 INK4A genes were
